4.7 Article

Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESCWorking Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiovascular Interventions (EAPCI)

期刊

EUROPEAN HEART JOURNAL
卷 42, 期 27, 页码 2630-+

出版社

OXFORD UNIV PRESS
DOI: 10.1093/eurheartj/ehab271

关键词

Percutaneous coronary intervention; Periprocedural myocardial injury; Periprocedural myocardial infarction; Type 4a myocardial infarction; Chronic coronary syndrome

资金

  1. Barts NIHR Cardiovascular Biomedical Research Centre
  2. Novo Nordisk Foundation [NNF14OC0013337, NNF15OC0016674]
  3. Danish Council for Strategic Research [11-108354]
  4. Trygfonden [109624]
  5. Ministero dell'Universita e della Ricerca, Progetti di Rilevante Interesse Nazionale [PRIN 2017 - 2017N8K7S2]
  6. National Institute for Health Research Biomedical Research Centre (NIHR-BRC) [BRC233/CM/SD/101320]
  7. British Heart Foundation [PG/18/44/33790, PG/16/85/32471]
  8. National Research, Development and Innovation Office of Hungary (Research Excellence Program -TKP/FIKP, National Heart Program) [NVKP 16-1-2016-0017]
  9. British Heart Foundation Clinical Study Grant [CS/15/7/316]
  10. Newcastle NIHR Biomedical Research Centre
  11. Astra Zeneca [ISSBRIL0303]
  12. National Institute for Health Research comprehensive Biomedical Research Centre
  13. King's College London
  14. Ministero dell'Istruzione, Universita e Ricerca Scientifica [2015583WMX]
  15. Programma STAR, Federico II University (Unina)
  16. Compagnia di San Paolo
  17. Netherlands Heart Foundation
  18. Horizon2020 ERC-2016-COG EVICARE [725229]
  19. Duke-National University Singapore Medical School
  20. Singapore Ministry of Health's National Medical Research Council [NMRC/CSA-SI/0011/2017, NMRC/CGAug16C006]
  21. COST (European Cooperation in Science and Technology) [CA16225]
  22. European Research Council (ERC) [725229] Funding Source: European Research Council (ERC)

向作者/读者索取更多资源

The article recommends measuring baseline and post-PCI cTn values in all CCS patients undergoing PCI and confirms the prognostic relevance of post-PCI cTn elevation >5x 99th percentile URL for defining type 4a MI. In the absence of related complications, the same cTn cut-off threshold can be used to define major periprocedural myocardial injury, which are strong predictors of all-cause mortality post-PCI and can be used as quality metrics in clinical trials. Further research is needed to evaluate treatment strategies for reducing the risk of major periprocedural myocardial injury, type 4a MI, and MACE in CCS patients undergoing PCI.
A substantial number of chronic coronary syndrome (CCS) patients undergoing percutaneous coronary intervention (PCI) experience periprocedural myocardial injury or infarction. Accurate diagnosis of these PCI-related complications is required to guide further management given that their occurrence may be associated with increased risk of major adverse cardiac events (MACE). Due to lack of scientific data, the cut-off thresholds of post-PCI cardiac troponin (cTn) elevation used for defining periprocedural myocardial injury and infarction, have been selected based on expert consensus opinions, and their prognostic relevance remains unclear. In this Consensus Document from the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiovascular Interventions (EAPCI), we recommend, whenever possible, the measurement of baseline (pre-PCI) cTn and post-PCI cTn values in all CCS patients undergoing PCI. We confirm the prognostic relevance of the post-PCI cTn elevation >5x 99th percentile URL threshold used to define type 4a myocardial infarction (MI). In the absence of periprocedural angiographic flow-limiting complications or electrocardiogram (ECG) and imaging evidence of new myocardial ischaemia, we propose the same post-PCI cTn cut-off threshold (>5x 99th percentile URL) be used to define prognostically relevant 'major' periprocedural myocardial injury. As both type 4a MI and major periprocedural myocardial injury are strong independent predictors of all-cause mortality at 1 year post-PCI, they may be used as quality metrics and surrogate endpoints for clinical trials. Further research is needed to evaluate treatment strategies for reducing the risk of major periprocedural myocardial injury, type 4a MI, and MACE in CCS patients undergoing PCI.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据